No difference was detected in the proportion of other poor prognosis features including advanced (pathologic prognostic stage IIA or higher), clinical stage IIB or higher, >34 mm, lymph node‐positive, PR‐negative, or HER2‐positive breast cancers (all p > 0.05; Table 3). This evidence concerns the gene ERBB2 and breast cancer.